EBR Systems receives FDA approval to start clinical trial of its wireless cardiac pacing system

The FDA granted EBR Systems an investigational device exemption to begin a clinical trial to evaluate the company’s wireless cardiac pacing system for patients with heart failure.

EBR Systems plans on starting the prospective, randomized study in mid-2017. The company expects to enroll 350 patients who failed conventional cardiac resynchronization therapy (CRT) or were previously unable to be treated with conventional CRT systems.

The wireless, endocardial cardiac pacing system incorporates EBR Systems’s Wise (Wireless Stimulation Endocardially) technology for CRT and stimulates the heart’s left ventricle. The technology is already approved in Europe.

Vivek Reddy, MD, a cardiologist and professor at Mt. Sinai Hospital in New York, presented results of EBR Systems’ SELECT-LV study in May at the Heart Rhythm Society scientific sessions in San Francisco. The study found that 34 of 35 patients who had failed conventional CRT therapy were implanted successfully with WiSE technology. In addition, 85 percent of patients improved their clinical composite score at six months.

EBR Systems said the WiSE technology could potentially benefit 1.5 million patients worldwide.

“Patients who have failed conventional CRT continue to deteriorate from their heart failure and are repeatedly subjected to costly hospitalizations,” William Abraham, MD, director of Ohio State University’s Wexner Medical Center and member of the study’s steering committee, said in a news release. “We have actively sought new treatment alternatives for this large and growing patient population. WiSE is easily the most promising solution to this costly problem. Its tiny receiver makes endocardial, left ventricular pacing possible for the first time. There is nothing like it in cardiology.”

Tim Casey,

Executive Editor

Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.

Around the web

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.